Clinical trials
Multiple Sclerosis trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
89 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 4 |
| 2006 | 5 |
| 2007 | 6 |
| 2008 | 3 |
| 2009 | 8 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 57 |
| Terminated | 9 |
| Unknown status | 9 |
| Recruiting | 7 |
| Active, not recruiting | 6 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 16 |
| Amsterdam UMC, location VUmc | 11 |
| Bayer | 6 |
| Novartis Pharmaceuticals | 6 |
| Sanofi | 5 |
| University Medical Center Groningen | 5 |
| Genzyme, a Sanofi Company | 4 |
| Hoffmann-La Roche | 3 |
| Actelion | 2 |
| GlaxoSmithKline | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 89 |
| Multiple Sclerosis, Relapsing-Remitting | 13 |
| Recurrence | 6 |
| Multiple Sclerosis, Chronic Progressive | 5 |
| Fatigue | 3 |
| Stroke | 3 |
| Nervous System Diseases | 2 |
| Parkinson Disease | 2 |
| Amyotrophic Lateral Sclerosis | 1 |
| Autoimmune Diseases of the Nervous System | 1 |
Trials
Showing 76 to 89 of 89. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.